Go to content
UR Home

Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis

Lohaus, Raphaela ; Michel, Jonathan ; Mayer, Katharina ; Lahmann, Anna Lena ; Byrne, Robert A. ; Wolk, Annabelle ; ten Berg, Jurrien M. ; Neumann, Franz-Josef ; Han, Yaling ; Adriaenssens, Tom ; Tölg, Ralph ; Seyfarth, Melchior ; Maeng, Michael ; Zrenner, Bernhard ; Jacobshagen, Claudius ; Wöhrle, Jochen ; Kufner, Sebastian ; Morath, Tanja ; Ibrahim, Tareq ; Bernlochner, Isabell ; Fischer, Marcus ; Schunkert, Heribert ; Laugwitz, Karl-Ludwig ; Mehilli, Julinda ; Kastrati, Adnan ; Schulz-Schüpke, Stefanie


In patients presenting with acute coronary syndrome (ACS) the optimal duration of dual-antiplatelet therapy after drug-eluting stent (DES) implantation remains unclear. At 6 months after intervention, patients receiving clopidogrel were randomly assigned to either a further 6-month period of placebo or clopidogrel. The primary composite endpoint was death, myocardial infarction, stent thrombosis, ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons